Replies to post #163732 on Biotech Values

[biocqr]

I was following that... did a some cursory DD and took a position. Based on pipeline, milestones, partnerships, cash position... looks cheap at first look.

[oc631]

Twitter dialogue on number of pills in ABBV/ENTA’s all-oral regimen and whether it matters:

Pill burden shouldn't be an issue yet tolerability in the real world setting can only be reduced by multiple classes of DAA's including ritonavir.



[ACHN] Any further mention of sovaprevir adversely reacting with ritonavir in the DDI study?